Tyme Technologies (Tyme Technologies) Construction In Progress : $0.00 Mil (As of Jun. 2022)

View and export this data going back to 2012. Start your Free Trial

What is Tyme Technologies Construction In Progress?

Tyme Technologies Construction In Progress Historical Data

The historical data trend for Tyme Technologies's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyme Technologies Construction In Progress Chart

Tyme Technologies Annual Data

Trend

Nov12

Nov13

Nov14

Dec15

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Construction In Progress

Get a 7-Day Free Trial

Tyme Technologies Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Tyme Technologies Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Tyme Technologies (Tyme Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyme Technologies Inc (NAS:TYME) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Pluckemin Way, Suite 103, Bedminster, NJ, USA, 07921

Website

https://www.tymeinc.com

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Executives

Michael Demurjian	director, 10 percent owner, officer: Chief Operating Officer	157 BROAD STREET SUITE 304 RED BANK NJ 07701
Steve Hoffman	director, 10 percent owner, officer: CEO and Chief Science Officer	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Christine D. Baker	director	C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK NY 10118
James Biehl	director	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Frank L. Porfido	officer: Chief Financial Officer	C/O TYME TECHNOLOGIES, INC. 1 PLUCKEMIN WAY, SUITE 103 BEDMINSTER NJ 07921
Barbara Galaini	officer: Corporate Controller	17 STATE STREET 7TH FLOOR NEW YORK NY 10004
David Carberry	director	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Van Tornout Jan M	officer: Acting Chief Medical Officer	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Douglas A Michels	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
John M. Rothman	officer: EVP, Product Development	1 PLUCKEMIN WAY SUITE 103 BEDMINSTER NJ 07921
Ben R Taylor	officer: President and CFO	44 WALL STREET 12TH FLOOR NEW YORK NY 10005
Michele Ilene Korfin	officer: Chief Operating Officer	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Donald W Degolyer	director	400 PROFESSIONAL DR. STE. 400, GAITHERSBURG MD 20879
Tommy G Thompson	director	7711 CARONDELET, ST. LOUIS MO 63105